1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Immunotherapy Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Global Immunotherapy Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. COVID-19 Impact Analysis
6. Global Immunotherapy Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Immunomodulators
6.3.3. Cell Therapy
6.3.4. Others (Vaccines, etc.)
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Immunotherapy Drugs Market Analysis and Forecast, by Therapy Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapy Area, 2017–2031
7.3.1. Cancer
7.3.2. Autoimmune Diseases
7.3.3. Infectious Diseases
7.3.4. Others
7.4. Market Attractiveness Analysis, by Therapy Area
8. Global Immunotherapy Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. Online Pharmacies
8.3.3. Hospital Pharmacies
9. Global Immunotherapy Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Immunotherapy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Immunomodulators
10.2.3. Cell Therapy
10.2.4. Others (Vaccines, etc.)
10.3. Market Value Forecast, by Therapy Area, 2017–2031
10.3.1. Cancer
10.3.2. Autoimmune Diseases
10.3.3. Infectious Diseases
10.3.4. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Online Pharmacies
10.4.3. Hospital Pharmacies
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Therapy Area
10.5.3. By Distribution Channel
10.5.4. By Country
11. Europe Immunotherapy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Immunomodulators
11.2.3. Cell Therapy
11.2.4. Others (Vaccines, etc.)
11.3. Market Value Forecast, by Therapy Area, 2017–2031
11.3.1. Cancer
11.3.2. Autoimmune Diseases
11.3.3. Infectious Diseases
11.3.4. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Online Pharmacies
11.4.3. Hospital Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Therapy Area
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Immunotherapy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Immunomodulators
12.2.3. Cell Therapy
12.2.4. Others (Vaccines, etc.)
12.3. Market Value Forecast, by Therapy Area, 2017–2031
12.3.1. Cancer
12.3.2. Autoimmune Diseases
12.3.3. Infectious Diseases
12.3.4. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Online Pharmacies
12.4.3. Hospital Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Therapy Area
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Immunotherapy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Immunomodulators
13.2.3. Cell Therapy
13.2.4. Others (Vaccines, etc.)
13.3. Market Value Forecast, by Therapy Area, 2017–2031
13.3.1. Cancer
13.3.2. Autoimmune Diseases
13.3.3. Infectious Diseases
13.3.4. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Online Pharmacies
13.4.3. Hospital Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Therapy Area
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Immunotherapy Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Immunomodulators
14.2.3. Cell Therapy
14.2.4. Others (Vaccines, etc.)
14.3. Market Value Forecast, by Therapy Area, 2017–2031
14.3.1. Cancer
14.3.2. Autoimmune Diseases
14.3.3. Infectious Diseases
14.3.4. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Online Pharmacies
14.4.3. Hospital Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Therapy Area
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global Immunotherapy Drugs Market, Company Share Analysis (2022)
15.2. Company Profiles
15.2.1. Bristol Myers Squibb
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Merck KGaA, Inc.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Novartis AG
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. AstraZeneca
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Pfizer
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Amgen
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Regeneron Pharmaceuticals Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. F. Hoffmann-La Roche AG
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. Eli Lilly and Company
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. Financial Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
